364 results on '"De Lena M"'
Search Results
52. Multicenter randomised trial of paclitaxel (P) maintenance chemotherapy (CT) versus control in metastatic breast cancer (MBC) patients achieving a response or stable disease to first-line CT including anthracyclines and paclitaxel: Final results from the Italian MANTA study
53. A phase II randomized trial of cisplatin/paclitaxel plus lonidamine versus cisplatin/ifosfamide plus lonidamine in the treatment of ovarian cancer
54. Phase II of oral vinorelbine (NVB oral) in combination with Cisplatin (P) followed by NVB oral single agent as consolidation therapy in advanced non small-cell lung cancer (NSCLC): A Patient's Benefit Analysis
55. Rationale for the use of gemcitabine in breast cancer (Review)
56. 823 A full navelbine oral (NVB oral) treatment in combination with cisplatin (P) followed by NVB oral single agent as consolidation therapy in advanced non small-cell lung cancer (NSCLC)
57. Adjuvant hormonetherapy for slow proliferating node-negative breast cancer patients. Results of the phase III trial of NCl-Bari
58. Adjuvant polychemotherapy vs control for node-negative, rapidly proliferating breast cancer: Combined analysis of two phase III trials
59. Phase I/II study of gemcitabine plus mitoxantrone as salvage chemotherapy in metastatic breast cancer
60. Metastatic malignant melanoma of the gallbladder
61. Epithelial ovarian cancer: Second and third line chemotherapy (Review)
62. Current status and future potential role of exemestane in the treatment of early and advanced breast cancer (Review)
63. AIDS-related non-Hodgkin's lymphoma: Clinico-pathological characteristics and therapeutic strategies (Review)
64. mdm2-p53 Interaction: Lack of Correlation with the Response to 5-Fluorouracil in Advanced Colorectal Cancer
65. Taxol, gemcitabine and vinorelbine, a very active platinum free triplet in naive patients with Non Small Cell Lung Cancer
66. Taxol-gemcitabine-vinorelbine (TGV) given every 2 weeks in chemo-naive advanced NSCLC. A SICOG phase I study
67. Oxaliplatin (L-OHP) and irinotecan (CPT-11) with 6s-leucovorin (IFA)-modulated 5-fluorouracil (FU) i.v. bolus every 2 weeks: a dose-finding study in patients (pts) with gastrointestinal malignancies
68. New aromatase inhibitors in the treatment of advanced breast cancer.
69. Gemcitabine + vinorelbine (GV) yields better survival than vinorelbine (V) alone in elderly non-small cell lung cancer (NSCLC) patients. Final analysis of a Southern Italy Cooperative Oncology Group (SICOG) phase III trial
70. Cisplatin-gemcitabine, vs. cisplatin-gemcitabine-vinorelbine, vs. cisplatin-gemcitabine-paclitaxel in advanced non-small-cell lung cancer. First-stage analysis of a Southern Italy Cooperative Oncology Group (SICOG) phase III trial
71. Thymidilate synthase and p53 primary tumour expression as predictive factors for advanced colorectal cancer patients
72. CEOP-B/VIMB vs. promace-CytaBOM in the treatment of intermediate or high grade non-Hodgkin's lymphoma: A randomised multicenter study of Southern Italy Cooperative Group.
73. A new protocol of iron therapy combined with epoetin alpha as a treatment for preoperative autologous blood donation in gynaecological tumor surgery.
74. Gemcitabine/cisplatin in advanced transitional cell carcinoma of the urinary tract (TCC): a phase II multicenter trial
75. Gemcitabine + vinorelbine (GV) vs vinorelbine (V) alone in elderly or frail non-small cell lung cancer (NSCLC) patients. Interim analysis of a SICOG phase III trial
76. Phase I/II study of gemcitabine plus mitoxantrone in advanced breast cancer (ABC)
77. The utility of a growth factor: r-HuEPO as a treatment for preoperative autologous blood donation in gynecological tumor surgery.
78. A phase II study of gemcitabine in patients with transitional cell carcinoma of the urinary tract previously treated with platinum
79. nm23 expression in human breast cancer: correlation with cell proliferation (S-phase) as observed with a double-labeling immunocytochemical-autoradiographic technique.
80. Neoadjuvant chemotherapy with accelerated CNF plus G-CSF in patients with breast cancer tumors larger than three centimeters: a pilot study.
81. Revertant and potentiating activity of lonidamine in patients with ovarian cancer previously treated with platinum.
82. 314 Patterns of failure in patients affected with non small cell lung cancer (NSCLC) treated with neoadjuvant chemotherapy
83. Subcutaneous recombinant interleukin-2 plus chemotherapy with cisplatin and dacarbazine in metastatic melanoma
84. Treatment of Advanced Urothelial Carcinoma with M-VECA (Methotrexate, Vinblastine, Epirubicin and Carboplatin)
85. 1147 Gemcitabine in resistant stage IV bladder cancer: A phase II study
86. Heterogeneity of intratumour proliferative activity in primary breast cancer: Biological and clinical aspects
87. CEOP-B alternated with VIMB in intermediate-grade and high-grade non-Hodgkin's lymphoma: a pilot study.
88. Long-term Subcutaneous Recombinant Interleukin-2 as Maintenance Therapy: Biological Effects and Clinical Implications
89. A shared effort toward better quality of care. The Consensus Conference on Breast Cancer Follow-up
90. Expression of Gst-Mu Transferase in Breast Cancer Patients and Healthy Controls
91. Tpa-Cyk Assay in Cytosol from Primary Breast Cancer: Preliminary Results
92. Cisplatin (CDDP) plus lonedamine (LND) in advanced ovarian cancer pretreated with CDDP or carboplatin (CBDCA)
93. Modification of Soluble Immunological Parameters during Treatment with Interleukin-2
94. Carboplatin plus ifosfamide as salvage treatment of epithelial ovarian cancer: a pilot study.
95. Solid-phase extraction of fluoropyrimidine derivatives on a copper-modified strong cation exchanger: determination of doxifluridine, 5-fluorouracil and its main metabolites in serum by high-performance liquid chromatography with ultraviolet detection
96. Phase I study of carboplatin, epirubicin and VP-16 plus G-CSF in extensive small cell lung cancer (SCLC)
97. Cytosolic Levels of Estrogen-Regulated pS2 Protein in Breast Cancer: Correlation with Tumor Proliferative Activity
98. HER-2/Neu Gene in Primary and Local Metastatic Axillary Lymph Nodes in Human Breast Tumors
99. Clinical-biological characterization of second neoplasm patients
100. Peripheral hemato-immunological modifications induced by subcutaneous (SC) rIL-2 treatment of advanced neoplasms
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.